Reviewing the mechanism of action of thiopurine drugs: Towards a new paradigm in clinical practice

Medical Science Monitor

Volumn 10, Issue 11, 2004, Pages

  Cara, Carlos J ^a,h   Pena, Amado Salvador ^b   Sans, Miquel ^c   Rodrigo, Luis ^d   Guerrero Esteo, Mercedes ^a   Hinojosa, Joaquín ^e   García Paredes, Julio ^f   Guijarro, Luis G ^g  

^a Celltech Pharma   (Spain)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^e HOSPITAL DE SAGUNTO   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^g UNIVERSITY OF ALCALÁ   (Spain)

^h Celltech Pharma SA   (Spain)

Author keywords

Apoptosis; Azathioprine; Mechanism of action; Thioguanine; TPMT

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

APOPTOSIS; BONE MARROW TOXICITY; CLINICAL PRACTICE; DRUG MECHANISM; DRUG METABOLISM; GENETIC VARIABILITY; IMMUNOSUPPRESSIVE TREATMENT; REVIEW;

APOPTOSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PURINES; SULFUR COMPOUNDS;

EID: 9144252139     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Lennard L, Rees CA, Lilleyman JS, Maddocks JL: Childhood leukemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol, 1983; 16: 359-63
2. Lennard L, Lilleyman JS: Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol, 1989; 7: 1816-23
3. Bloomfeld RS, Onken JE: Mercaptopurine metabolite results in clinical gastroenterology practice. Aliment Pharmacol Ther, 2003; 17: 69-73
4. Derijks LJ, De Jong DJ, Gilissen LP et al: 6-TG seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur J Gastroenterol Hepatol, 2003; 15: 63-67
5. Krynetski EY, Evans WE: Pharmacogenetics as a molecular basis for individualized drug therapy: The thiopurine S-methyltransferase paradigm. Pharm Res, 1999; 16: 342-49
6. Krynetskaia NF, Krynetski EY, Evans WE: Human RnaseH-mediated RNA cleavage from DNA-RNA duplexes is inhibited by 6-deoxyguanosine incorporation into DNA. Mol Pharmacol, 1999; 56: 841-48
7. Weinshilboum RM, Sladek SL: Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet, 1980; 32: 651-62
8. Menor C, Fueyo J, Escribano O et al: Thiopurine methyltransferase activity in a Spanish population sample: decrease of enzymatic activity in multiple sclerosis patients. Mult Scler, 2002; 8: 243-48
9. Menor C, Fueyo JA, Escribano O et al: Determination of Thiopurine Methyltransferase Activity in Human Erythrocytes by High-Performance Liquid Chromatography: Comparison With the Radiochemical Method. Ther Drug Monitor, 2001; 23: 536-41
10. Anstey A, Lennard L, Mayou SC, Kirby JD: Pancytopenia related to azathioprine - an enzyme deficiency caused by a common genetic polymorphism: a review. J R Soc Med, 1992; 85: 752-56
11. Lowry PW, Franklin CL. Weaver AL et al: Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut, 2001; 49: 665-70
12. Cuffari C, Hunt S, Bayless T: Utilisation of erythrocyte 6-thioguanine metabolite levels to optimize azathioprine therapy in patients with inflammatory bowel disease. Gut, 2001; 48: 642-46
13. Dubinsky MC, Hassard PV, Seidman EG et al: An Open-Label Pilot Study Using Thioguanine as a Therapeutic Alternative in Crohn's Disease Patients Resistant to 6-Mercaptopurine Therapy. Inflammatory Bowel Diseases, 2001; 7: 181-89
14. --triphosphates by DNA polymerase alpha: affinity, interaction, and consequences. Clin Cancer Res, 1997; 3: 1347-55
15. Lipp HP, Bokemeyer C: Clinical pharmacokinetics of cytostatic drugs: efficacy and toxicity, in Anticancer Drug Toxicity (Lipp HP ed), Marcel Dekker, Inc., New York, pp 114-56
16. Lennard L: The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol, 1992; 43: 329-39
17. Swan PF, Waters TR, Moulton DC et al: Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science, 1996; 273: 1109-11
18. Tay BS, Lilley RM, Murray AW, Atkinson MR: Inhibition of phosphoribosyl pyrophosphate amidotransferase from Ehrlich ascites-tumor cells by thiopurine nucleotides. Biochem Pharmacol, 1969; 18: 936-38
19. Allan PW, Bennet LL: 6-Methylthioguanylic acid, a metabolite of 6-thioguanine. Biochem Pharmacol, 1971; 20: 847-52
20. Elion GB: The purine path to chemotherapy. Science, 1989; 244: 41-47
21. Erb N, Harms DO, Janka-Schaub G: Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-TG versus 6-MP. Cancer Chemother Pharmacol, 1998; 42: 266-72
22. Relling MV, Hancock ML, Boyett JM et al: Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood, 1999; 93: 2817-23
23. Evans WE, Horner M, Chu YQ et al: Altered mercaptopurine metabolism, toxic effects and dosage requirements in a thyopurine methyltransferase- deficient child with acute lymphocytic leukemia. J Pediatr, 1991; 119: 985-89
24. Relling MV, Hancock ML, Rivera GK et al: Mercaptopurine therapy intolerance and heterozigosity at the thiopurine S-methyltranferase gene locus. J Natl Cancer Inst (Bethesda), 1999; 91: 2001-8
25. Evans WE, Relling MV: Mercaptopurine vs thioguanine for the treatment of acute lymphoblastic leukemia. Leuk Res, 1994; 18: 811-14
26. Dervieux T, Blanco JG, Krynetski EY et al: Differing contribution of thiopurine methyl transferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res, 2001; 61: 5810-16
27. Ellis RE, Yuan JY, Horvitz HR: Mechanism and function of cell death. Annu Rev Cell Biol, 1991; 7: 663-98
28. Gerschenson LE, Rotello RJ: Apoptosis: a different type of cell death. FASEB J, 1992; 6: 2450-55
29. Leist M, Single B, Castoldi AF et al: Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med, 1997; 185: 1481-86
30. Thornberry A. Labzenik Y: Caspase: enemies within. Science, 1998; 281: 1312-16
31. Ashkenazi A, Dixit VM: Death receptors: signaling and modulation. Science, 1998; 281: 1305-8
32. Chiou SK, Jones MK, Tarnawski AS: Survivin - an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med Sci Monit, 2003; 9(4): PI43-PI47
33. Kroemer G, Dallaporta B, Resche-Rigon M: The mitochondrial death/ life regulator in apoptosis and necrosis. Annu Rev Physiol, 1998; 60: 619-42
34. Wei MC, Zong WX, Cheng E et al: Pro-apoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science, 2001; 292: 727-30
35. Reed JC: BCL-2; Prevention of apoptosis as a mechanism of drug resistance. Hematol/oncol Clin, 1995; 9: 451-73
36. Coulthard SA, Hall AG: Recent advances in the pharmacogenomics of thiopurine methyltransferase. Pharmacogenomics J, 2001; 1: 254-61
37. Swann PF, Waters TR, Moulton DC et al: Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science, 1996; 273: 1109-11
38. Glaab WE, Risinger JI, Umar A et al: Resistance to 6-thioguanine in mismatch repair-deficient human cancer cell lines correlates with an increase in induced mutations at the HPRT locus. Carcinogenesis, 1998; 19: 1931-37
39. Krynetskaia NF, Krynetski EY, Evans WE: Human RNAse H-mediated RNA cleavage from DNA-RNA duplexes is inhibited by 6-deoxythioguanosine incorporation into DNA. Mol Pharmacol, 1999; 56: 841-48
40. Tendian SW, Parker WB: Interaction of deoxyguanosine nucleotide analogs with human telomerase. Mol Pharmacol, 2000; 57: 695-99
41. Hawn MT, Umar A, Carathers JM et al: Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res, 1995; 55: 3721-25
42. Krynetski EY, Krynetskaia NF, Gallo AE et al: A novel protein complex distinct from mismatch repair binds thioguanylated DNA. Mol Pharmacol., 2001; 59: 367-74
43. Krynetskaia NF, Brenner TL, Krynetski EY et al: Msh2 deficiency attenuates but does not abolish tiopurine hematopoietic toxicity in Msh2-/-mice. Mol Pharmacol 2003; 64: 456-65
44. Sirover MA: New insights into an old protein: the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase. Biochim Biophys Acta, 1999; 1432: 159-84
45. Sawa A, Khan AA. Hester LD. Snyder SH: Glyceraldehyde-3-phosphate dehydrogenase: nuclear translocation participates in neuronal and non-neuroual cell death. Proc Natl Acad Sci USA, 1997; 11669-74
46. Krynetsky EY, Krynetskaia NF, Bianchi ME, Evans WE: A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, Erp60, and Glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues. Cancer Res 2003; 63: 100-6
47. Krynetskaia NF, Feng JY, Krynetski EY et al: Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug. FASEB J, 2001; 15: 1902-8
48. Ling YH, Chan JY, Beattie KL, Nelson JA: Consequences of 6-thioguanine incorporation into DNA on polymerase, ligase, and endonuclease reactions. Mol Pharmacol, 1992; 42: 802-7
49. Krynetskaia NF, Cai X, Nitiss JL et al: Thioguanine substitution alters DNA cleavage mediated by topoisomerase II. FASEB J, 2000; 14: 2339-44
50. June CH, Bluestone JA, Nadler LM, Thompson CB: The B7 and CD28 receptor families. Immunol Today, 1994; 15: 321-31
51. Radvanyi LG, Shi Y, Vaziri H et al: CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. J Immunol, 1996; 156: 1788-98
52. Sperling AI, Auger JA, Ehst BD et al: CD28/B7 interactions deliver a unique signal to naïve T cells that regulates cell survival but not early proliferation. J Immunol, 1996; 157: 3909-17
53. Boise LH, Minn AJ, Noel PJ et al: CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity, 1995; 3: 87-98
54. Tiede I, Fritz G, Strand S et al: CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest, 2003; 111: 1133-45
55. Dahl AM, Klein C, Andres PG et al: Expression of bcl-x(L) restores cell survival, but not proliferation of effector differentiation, in CD28-deficient T lymphocytes. J Exp Med, 2000; 191: 2031-38
56. Cara C, Gomollon F, Gisbert J et al: Thiopurine methyl transferase (TPMT) phenotype in a large group of inflammatory bowel disease patients and control population in Spain. Digestive Disease Week, American Gastroenterology Association; 2002 May 19-22; San Francisco, USA